Smith & Nephew is a global medical device company. The company markets clinically superior products, principally in orthopaedics, endoscopy and wound management to deliver cost-effective solutions, significant physicianadvantage and real patient benefits. A continuous process of supplying new and innovative products is supported by substantial R&D investment todeliver new levels of healing to patients throughout the world
| Revenue (Most Recent Fiscal Year) | $5.14B |
| Net Income (Most Recent Fiscal Year) | $600.00M |
| PE Ratio (Current Year Earnings Estimate) | 31.37 |
| PE Ratio (Trailing 12 Months) | -- |
| PEG Ratio (Long Term Growth Estimate) | 5.89 |
| Price to Sales Ratio (Trailing 12 Months) | -- |
| Price to Book Ratio (Most Recent Quarterly Book Value per Share) | 3.56 |
| Price to Cash Ratio (Most Recent Annual Cash Flow per Share) | 12.64 |
| Pre-Tax Margin (Trailing 12 Months) | 14.46% |
| Net Margin (Trailing 12 Months) | -- |
| Return on Equity (Trailing 12 Months) | -- |
| Return on Assets (Trailing 12 Months) | -- |
| Current Ratio (Most Recent Fiscal Quarter) | 2.18 |
| Quick Ratio (Most Recent Fiscal Quarter) | 1.04 |
| Debt to Common Equity (Most Recent Fiscal Quarter) | 0.50 |
| Inventory Turnover (Trailing 12 Months) | 0.85 |
| Book Value per Share (Most Recent Fiscal Quarter) | $11.76 |
| Earnings per Share (Most Recent Fiscal Quarter) | -- |
| Earnings per Share (Most Recent Fiscal Year) | $2.04 |
| Diluted Earnings per Share (Trailing 12 Months) | -- |
| Exchange | NYSE |
| Sector | Healthcare |
| Industry | Medical Devices |
| Common Shares Outstanding | 437.77M |
| Free Float | 433.40M |
| Market Capitalization | $17.65B |
| Average Volume (Last 20 Days) | 0.25M |
| Beta (Past 60 Months) | 0.55 |
| Percentage Held By Insiders (Latest Annual Proxy Report) | 1.00% |
| Percentage Held By Institutions (Latest 13F Reports) | 9.12% |
| Annual Dividend (Based on Last Quarter) | $0.90 |
| Dividend Yield (Based on Last Quarter) | 2.24% |